Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study

[1]  P. Quaglino,et al.  Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden? , 2021, The Journal of dermatological treatment.

[2]  M. Lebwohl,et al.  The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up , 2021, The British journal of dermatology.

[3]  P. Gisondi,et al.  IL‐17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review , 2021, Dermatologic therapy.

[4]  A. Costanzo,et al.  Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population , 2021, The Journal of dermatological treatment.

[5]  P. Gisondi,et al.  EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  M. Chimenti,et al.  Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study , 2021, RMD Open.

[7]  L. Marchand,et al.  Immunotherapies in cutaneous pathologies: an overview. , 2020, Drug discovery today.

[8]  C. Foti,et al.  Effectiveness and safety of secukinumab in patients with moderate‐severe psoriasis: A multicenter real‐life study , 2020, Dermatologic therapy.

[9]  M. Galán-Gutiérrez,et al.  Drug survival, discontinuation rates, and safety profile of secukinumab in real‐world patients: a 152‐week, multicenter, retrospective study , 2020, International journal of dermatology.

[10]  L. Skov,et al.  Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis. , 2020, JAMA dermatology.

[11]  M. Augustin,et al.  Secukinumab is effective in treatment of moderate‐to‐severe plaque psoriasis: real‐life effectiveness and safety from the PROSPECT study , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[12]  C. Peralta,et al.  Real‐world evidence of secukinumab in psoriasis treatment – a meta‐analysis of 43 studies , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  G. Pellacani,et al.  A real‐life experience of psoriatic patients with history of cancer treated with biological drugs , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[14]  L. Coates,et al.  Long‐term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[15]  Xiaoxia Li,et al.  The role of interleukin-17 in tumor development and progression , 2019, The Journal of experimental medicine.

[16]  Xiaoyu Jiang,et al.  IL-17A inhibition by secukinumab induces early clinical, histopathological, and molecular resolution of psoriasis. , 2019, The Journal of allergy and clinical immunology.

[17]  G. Argenziano,et al.  Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study , 2019, Expert opinion on biological therapy.

[18]  A. Deodhar,et al.  Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data , 2019, Arthritis Research & Therapy.

[19]  A. Gottlieb,et al.  Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study , 2017, Rheumatology.

[20]  K. Reich,et al.  Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. , 2016, Journal of the American Academy of Dermatology.

[21]  Daniel B. Shin,et al.  The Risk of Cancer in Patients With Psoriasis: A Population-Based Cohort Study in the Health Improvement Network. , 2016, JAMA dermatology.

[22]  F. Vanaclocha,et al.  Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. , 2015, Journal of the American Academy of Dermatology.

[23]  M. Lebwohl,et al.  IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies , 2015, The Journal of investigative dermatology.

[24]  B. Elewski,et al.  Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.

[25]  M. Maître,et al.  Risk of cancer in psoriasis: a systematic review and meta‐analysis of epidemiological studies , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[26]  B. Strober,et al.  Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up , 2013, The British journal of dermatology.

[27]  G. Burmester,et al.  Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease , 2012, Annals of the rheumatic diseases.

[28]  C. Dong.  IL-23/IL-17 Biology and Therapeutic Considerations , 2008, Journal of immunotoxicology.

[29]  I. Belinchón Romero,et al.  A prospective multi-center study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients. , 2019, Journal of the American Academy of Dermatology.